These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 7572687)

  • 1. Unresolved issues in early trials of cholesterol lowering.
    LaRosa JC
    Am J Cardiol; 1995 Sep; 76(9):5C-9C. PubMed ID: 7572687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-density lipoproteins and risk for coronary artery disease.
    Ballantyne CM
    Am J Cardiol; 1998 Nov; 82(9A):3Q-12Q. PubMed ID: 9819098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "The lower the better" in hypercholesterolemia therapy: a reliable clinical guideline?
    Jacobson TA
    Ann Intern Med; 2000 Oct; 133(7):549-54. PubMed ID: 11015169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low density lipoprotein cholesterol: is lower better?
    Leiter LA
    Can J Cardiol; 2000 Jan; 16 Suppl A():20A-2A. PubMed ID: 10653927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials.
    Eisenberg DA
    Am J Med; 1998 Feb; 104(2A):2S-5S. PubMed ID: 9550499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieving optimal lipid goals in patients with coronary artery disease.
    Karalis DG; Subramanya RD; Hessen SE; Liu L; Victor MF
    Am J Cardiol; 2011 Mar; 107(6):886-90. PubMed ID: 21247526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S).
    Kjekshus J; Pedersen TR
    Am J Cardiol; 1995 Sep; 76(9):64C-68C. PubMed ID: 7572690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk?
    Dean BB; Borenstein JE; Henning JM; Knight K; Merz CN
    Am Heart J; 2004 Jun; 147(6):966-76. PubMed ID: 15199342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Harvard Atherosclerosis Reversibility Project Research Group.
    Sacks FM; Gibson CM; Rosner B; Pasternak RC; Stone PH
    Am J Cardiol; 1995 Sep; 76(9):78C-85C. PubMed ID: 7572692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of lipid lowering in coronary artery disease.
    Goldberg AC
    Curr Opin Cardiol; 1997 Sep; 12(5):488-93. PubMed ID: 9352177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit of aggressive lipid-lowering therapy: insights from the post coronary artery bypass graft study and other trials.
    White CW
    Am J Med; 1998 Jul; 105(1A):63S-68S. PubMed ID: 9707270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Range of serum cholesterol values in the population developing coronary artery disease.
    Kannel WB
    Am J Cardiol; 1995 Sep; 76(9):69C-77C. PubMed ID: 7572691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
    Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
    Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of lipid disorders in the elderly.
    Playford DA; Watts GF
    Drugs Aging; 1997 Jun; 10(6):444-62. PubMed ID: 9205850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are we aggressive enough in lowering cholesterol?
    Waters DD
    Am J Cardiol; 2001 Aug; 88(4A):10F-5F. PubMed ID: 11520481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.